# A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

> **NCT03895203** · PHASE3 · COMPLETED · sponsor: **UCB Biopharma SRL** · enrollment: 852 (actual)

## Conditions studied

- Psoriatic Arthritis

## Interventions

- **DRUG:** Bimekizumab
- **DRUG:** Adalimumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03895203
- **Lead sponsor:** UCB Biopharma SRL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-03
- **Primary completion:** 2021-08-17
- **Final completion:** 2022-07-11
- **Target enrollment:** 852 (ACTUAL)
- **Last updated:** 2026-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03895203

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03895203, "A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT03895203. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*